ADGMHealthcare · Medical Devices

ADGM Stock Forecast: Adagio Medical Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$0.56

−3.28% on the day

The 3 Wall Street analysts covering Adagio Medical Holdings, Inc. hold a median 12-month price target of $3 — +434.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$12.5M

Ticker Nerd rank

37 / 100

Median analyst target

$3.00

Analysts covering

Revenue$0.0

Operating income−$4.9M

Net income−$6.7M

Free cash flow−$5.3M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+3.7%

−22.0%

YTD

−46.1%

−66.2%

From 52W high

−76.2%

From 52W low

+49.6%

$0.38

$2.36

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ADGM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adagio Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth

Size

Accruals

Revisions

Momentum

Volatility

Quality

Value

Issuance

Growth (94): Sales and profits are climbing, and climbing faster than before.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADGM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADGM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts

3 Buy0 Hold0 Sell

Low $3.00Median $3.00High $4.00

The green dot is the last close — the median target sits +434.8% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
3 June 2026	LUCID CAPITAL MARKETS	Initiates	Buy	$3.00
14 Apr 2026	Piper Sandler	Initiates	Overweight	—
2 Dec 2025	Lake Street	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADGM appears on the weeks it earns a place.

Performance

ADGM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Adagio Medical Holdings, Inc. returned −66.2% against +17.5% for the S&P 500, dividends included.

ADGM vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADGM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Adagio Medical Holdings, Inc. (ADGM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.4×
Price / sales: —
Price / book: −30.4×
EV / EBITDA: −1.6×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −657.8%
Return on assets: −35.5%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adagio Medical Holdings, Inc. (ADGM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Adagio Medical Holdings, Inc. has a market value of $12.5M and an enterprise value of $30.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$27.1M.
Diluted earnings per share, trailing twelve months: $−1.48.
Free cash flow in the twelve months to 30 June 2026: −$16.6M.
Shares outstanding: 22.2M.
Trailing P/E: −0.4×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Adagio Medical Holdings, Inc. employs 41 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

ADGM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
ADGMAdagio Medical Holdings, Inc.	$12.5M	37
SINTSINTX Technologies, Inc.	$11.4M	27
IRIXIRIDEX Corp.	$11.3M	80
PMIPicard Medical, Inc.	$12.5M	25
HSCSHeartSciences, Inc.	$13.2M	31
BMRABiomerica, Inc.	$10.3M	17
NMTCNeuroOne Medical Technologies Corp.	$14.2M	39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adagio Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADGM news & analysis

Adagio Medical Reports Second Quarter 2026 Results

Business Wire · 11 Aug 2026positive

Adagio Medical Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026. As a recent business highlight, the company treated the first patient with its next-generation vCLAS™ Ultra Ultra-Low temperature ablation catheter at the Hospital of the University of Pennsylvania.

Why it matters — ADGM watchers would care because the first-patient milestone for the next-generation vCLAS Ultra catheter signals progress in advancing the company's catheter ablation technology for cardiac arrhythmias.

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Business Wire · 3 Aug 2026positive

Adagio Medical announced the successful treatment of the first patient using its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (ULTA) system, under Expanded Access authorization from the U.S. Food and Drug Administration. The patient presented with non-ischemic cardiomyopathy, a type of cardiac arrhythmia condition the system is designed to treat.

Why it matters — This marks the first clinical use of Adagio's faster, single-freeze next-generation system, representing a key development milestone for the company's catheter ablation platform.

FAQ

Frequently asked questions about ADGM stock

What is the ADGM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Adagio Medical Holdings, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADGM stock a buy right now?

Of the 3 analysts covering Adagio Medical Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adagio Medical Holdings, Inc. 37 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADGM?

As at 12 Sept 2026, Adagio Medical Holdings, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will ADGM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +434.8% from the last close, and Ticker Nerd's factor model ranks Adagio Medical Holdings, Inc. 37 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADGM stock forecast for 2030?

No analyst covering Adagio Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADGM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has ADGM stock performed over the past year?

Adagio Medical Holdings, Inc. returned -66.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adagio Medical Holdings, Inc. do?

Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias.

What is the latest news on ADGM?

The most recent item we track (Business Wire, 11 Aug 2026): "Adagio Medical Reports Second Quarter 2026 Results". Adagio Medical Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026. As a recent business highlight, the company treated the first patient with its next-generation vCLAS™ Ultra Ultra-Low temperature ablation catheter at the Hospital of the University of Pennsylvania.

Company

About Adagio Medical Holdings, Inc.

Adagio Medical Holdings, Inc. is a medical technology company focused on developing and commercializing catheter-based ablation systems for the treatment of cardiac arrhythmias. Its current portfolio includes the iCLAS atrial ultra-low temperature ablation system, the vCLAS ventricular ultra-low temperature catheter platform, and Cryopulse pulsed field cryoablation catheters. These technologies are designed to support physicians treating rhythm disorders such as atrial fibrillation and ventricular tachycardia, with an emphasis on delivering targeted lesion creation in cardiac tissue. Adagio Medical Holdings, Inc. operates as a healthcare device company serving the electrophysiology market, where catheter ablation plays an important role in minimally invasive heart rhythm management. Headquartered in Laguna Hills, California, the company concentrates on clinical and commercial use cases across cardiac arrhythmia care.

CEO Mr. Todd Usen · 41 employees · United States · https://adagiomedical.com